Trials / Completed
CompletedNCT02115542
Single Agent Regorafenib in Refractory Advanced Biliary Cancers
Multi Institutional Phase II Trial of Single Agent Regorafenib in Refractory Advanced Biliary Cancers
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 39 (actual)
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to see if regorafenib can help control or decrease cancer size in patients with cancer of the bile duct. Researchers also want to find out if regorafenib is safe and tolerable.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Regorafenib | Four 40 mg regorafenib tables should be taken in the morning with approximately 8 fluid ounces (240 mL) of water after a low-fat (\<30% fat) breakfast. |
Timeline
- Start date
- 2014-06-05
- Primary completion
- 2018-12-10
- Completion
- 2021-09-20
- First posted
- 2014-04-16
- Last updated
- 2021-10-12
- Results posted
- 2020-01-13
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02115542. Inclusion in this directory is not an endorsement.